Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA4 | P22748 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TTPA | P49638 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22517795 | 0.96 | PTGS2 (0.40) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL16914691 | 0.90 | CA12 (0.49) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL20921400 | 0.89 | PTGS2 (0.34) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL17768307 | 0.88 | CA12 (0.47) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL6152189 | 0.88 | CA12 (0.47) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL16914733 | 0.86 | CA12 (0.45) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL22518095 | 0.84 | PTGS2 (0.33) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL16914783 | 0.81 | CA12 (0.43) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL4047297 | 0.81 | CA12 (0.47) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL22518011 | 0.81 | PTGS2 (0.30) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-2021324-B1 | NITRATED HETEROCYCLIC COMPOUNDS AS ENDOTHELIN RECEPTOR ANTAGONIST | NICOX SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-20090263472-A1 | ENDOTHELIN RECEPTOR ANTAGONIST DERIVATIVES | NICOX S.A. (FR) | 2009-10-22 | — | — | US | disclosed |
| CN-101454283-A | Nitrated heterocyclic compounds as endothelin receptor antagonists | NICOX SA (FR) | 2009-06-10 | — | — | CN | disclosed |
| EP-2021324-A1 | NITRATED HETEROCYCLIC COMPOUNDS AS ENDOTHELIN RECEPTOR ANTAGONIST | NicOx S.A. (FR) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007137980-A1 | NITRATED HETEROCYCLIC COMPOUNDS AS ENDOTHELIN RECEPTOR ANTAGONIST | NICOX S.A. (FR) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263472-A1 | ENDOTHELIN RECEPTOR ANTAGONIST DERIVATIVES | EDNRA, EDNRB, ECE1 | PTGS2 102/4885CA12 4780/4885CA1 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.